In8 Bio, Inc. financial data

Symbol
INAB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Empire State Building, 350 5 Th Avenue, Suite 5330, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Incysus Therapeutics, Inc. (to 9/20/2018)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 426 % -40.1%
Debt-to-equity 40.6 % +66.6%
Return On Equity -173 % -29.2%
Return On Assets -105 % -27.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.8M shares +48.1%
Common Stock, Shares, Outstanding 46.4M shares +51.7%
Entity Public Float 22.7M USD +285%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 45.1M shares +58.5%
Weighted Average Number of Shares Outstanding, Diluted 45.1M shares +58.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18.4M USD +10%
General and Administrative Expense 13.7M USD -2.4%
Operating Income (Loss) -32.3M USD -6.08%
Net Income (Loss) Attributable to Parent -32M USD -5%
Earnings Per Share, Basic -0.82 USD/shares +32.8%
Earnings Per Share, Diluted -0.82 USD/shares +32.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current 529K USD +91%
Assets, Current 12.7M USD -34.8%
Property, Plant and Equipment, Net 3.11M USD -21.8%
Operating Lease, Right-of-Use Asset 4.33M USD +12.2%
Other Assets, Noncurrent 320K USD +25.5%
Assets 22.5M USD -24.3%
Accounts Payable, Current 1.44M USD +147%
Accrued Liabilities, Current 1.53M USD -8.42%
Liabilities, Current 4.76M USD +25.9%
Operating Lease, Liability, Noncurrent 3.59M USD +9.55%
Liabilities 8.88M USD +12.1%
Retained Earnings (Accumulated Deficit) -108M USD -41.8%
Stockholders' Equity Attributable to Parent 13.6M USD -37.5%
Liabilities and Equity 22.5M USD -24.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.92M USD -6.45%
Net Cash Provided by (Used in) Financing Activities -277K USD -151%
Net Cash Provided by (Used in) Investing Activities -71K USD +83.5%
Common Stock, Shares Authorized 490M shares 0%
Common Stock, Shares, Issued 46.4M shares +51.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.27M USD -12.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.5M USD -39.3%
Deferred Tax Assets, Gross 20.7M USD +36.5%
Operating Lease, Liability 4.48M USD +11%
Depreciation 958K USD +73.6%
Payments to Acquire Property, Plant, and Equipment 50K USD -86.5%
Lessee, Operating Lease, Liability, to be Paid 5.75M USD +10%
Operating Lease, Liability, Current 887K USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.42M USD +15.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD +15.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +8.26%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.28M USD +6.86%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.22M USD +20.8%
Deferred Tax Assets, Operating Loss Carryforwards 2.7M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 891K USD +16.2%
Additional Paid in Capital 122M USD +24.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 19.6M USD +41.3%
Share-based Payment Arrangement, Expense 4.9M USD +32.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%